ライフサイエンスコーパス: beta particle

1 lf-absorption effect, typical for low-energy beta particles.

2 rgy transfer (LET) properties of high-energy beta particles.

3 f secondary electrons in c-Si by the primary beta-particles.

4 rgy-transfer (LET) properties of high-energy beta-particles.

5 varied significantly in their absorption of beta-particles.

6 nosis ((155)Tb) and for alpha- ((149)Tb) and beta(-)-particle ((161)Tb) therapy.

7 ionuclides that emit low-energy electrons or beta particles (169Er, 117mSn, and 33p) were evaluated.

8 tent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for

9 increase the steady-state level of apo B100-beta particles above that of apo B100 particles in contr

10 (64)Cu emits positrons as well as beta(-) particles and Auger and internal conversion elec

11 s a theranostic radionuclide that emits both beta(-) particles and Auger electrons with high linear e

12 -life to (177)Lu, but beyond the emission of beta(-)-particles and gamma-rays, (161)Tb also emits con

13 bution of a radioisotope that emits alpha or beta particles, and show empirically that the null funct

14 In recent years, new alpha-particle-, beta(-)-particle-, and Auger electron-emitting radiometa

15 the Au-198 isotope; the range of the (198)Au beta-particle (approximately 11 mm in tissue or approxim

16 alpha-therapy is a promising alternative to beta(-)-particle-based treatments.

17 gations, recent calculations have shown that beta particles, because of their helicity, radiolyse L-

18 tion of whether absorption and scattering of beta-particles by stent struts will cause significant pe

19 We also developed a solid-state beta-particle camera imbedded directly below the microfl

20 The limited range of beta-particles compared with gamma-radiation, however, o

21 models, radionuclide S values (electron and beta particle components only) were subsequently calcula

22 sed detector for real-time, high-sensitivity beta particle detection.

23 s (360 degrees view) of plaques by detecting beta-particles during (18)F-FDG decay.

24 Evidence supporting the use of beta-particle, electron, and alpha-particle-emitting rad

25 icidal absorbed doses (ADs) delivered by the beta-particle emissions of the radioactive iodine ((131)

26 g a radionuclide with short-range (alpha- or beta-particle) emissions.

27 om the penetrating nature of the high-energy beta particles emitted by the radionuclides.

28 The beta particles emitted from the (90)Sr generate blue lig

29 The short-range beta-particles emitted by [3H]dTTP result in self-irradi

30 Since the alpha- and beta-particles emitted during the decay of radioisotopes

31 EG) chains linked to DOTA for complexing the beta-particle emitter (177)Lu and to panitumumab for tar

32 notherapy with these bsRICs labeled with the beta-particle emitter (177)Lu or the Auger electron-emit

33 ent of neuroendocrine tumors (NETs) with the beta-particle emitter (177)Lu-DOTATATE is currently cons

34 The low-energy beta-particle emitter 33P appears to offer a substantial

35 stantial dosimetric advantage over energetic beta-particle emitters (e.g., 32p, 89Sr, 186Re) for irra

36 delivered by Ab LL1, both Auger electron and beta-particle emitters can produce specific and effectiv

37 a large dosimetric advantage over energetic beta-particle emitters for alleviating bone pain, and po

38 The beta-particle emitters had considerably higher levels of

39 rs, (111)In, 67Ga, and 125I, and to evaluate beta-particle emitters, 131I and 90Y.

40 kill than other Auger electron emitters and beta-particle emitters, using an anti-CD74 antibody (Ab)

41 ed currently for clinical dose estimates for beta-particle emitters.

42 ing copper-64 ((64)Cu, t (1/2) = 12.7 h) and beta particle-emitting copper-67 ((67)Cu, t (1/2) = 61.8

43 Unlike beta particle-emitting isotopes, alpha emitters can sele

44 Previously, we synthesized a beta-particle-emitting low-molecular-weight compound, (1

45 as to evaluate the dose-related effects of a beta-particle-emitting radioactive stent in a porcine co

46 The next-generation beta-particle-emitting radioimmunoconjugate (177)Lu-lilo

47 There were seven beta-particle-emitting radioisotope stents (32P, activit

48 inical nephrotoxicity analyses of alpha- and beta-particle-emitting radioligands exhibiting a heterog

49 Cerenkov luminescence, the light produced by beta-particle-emitting radionuclides such as clinical po

50 ivo bremsstrahlung with the high-energy pure beta-particle-emitting radionuclides used for therapeuti

51 y with (177)Lu-DOTATATE (DOTA-octreotate), a beta-particle-emitting somatostatin derivative, has demo

52 rivascular space of vessels treated with the beta-particle-emitting stent compared with control vesse

53 e of low-dose endovascular irradiation via a beta-particle-emitting stent inhibits neointimal formati

54 estigate whether low-dose irradiation from a beta-particle-emitting stent would inhibit neointimal pr

55 % versus 36.0 +/- 10.7%, P = .02) within the beta-particle-emitting stents compared with the control

56 (32)P beta-particle-emitting stents have adverse vascular effe

57 We studied the vascular effects of beta-particle-emitting stents in normal canine coronary

58 The arterial placement of (32)P beta-particle-emitting stents in various experimental an

59 erwent placement of 35 nonradioactive and 39 beta-particle-emitting stents with activity levels of 23

60 or DLL3-targeted radiotherapy, which employs beta-particle-emitting therapeutic radioisotopes conjuga

61 166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%

62 red more directly, with no dependency on the beta-particle energy.

63 The corresponding beta particles flux levels emitted from the recessed dis

64 rrow are comparable to the mean range of the beta particles for a wide variety of beta-emitting radio

65 Moreover, autoradiography, which recorded beta particles from (198)Au, enabled visualizing the het

66 ere obtained with only a few hundred emitted beta particles from the (90)Y/(90)Sr source or conversio

67 Relativistic beta particles from the nuclear decay of 90 Sr and 90Y g

68 biologic effectiveness equivalent to that of beta particles) from a low-dose rate 137Cs irradiator.

69 imaging system comprising a microchip and a beta-particle imaging camera permitted routine cell-base

70 ich introduced significant interference from beta particles in the scintillation pulse height spectra

71 previously reported because of absorption of beta-particles in the dermis.

72 mity to the radioisotope convert the emitted beta(-) particles into photons having wavelengths in the

73 erential response to the doses of continuous beta-particle irradiation used in this experimental mode

74 However, the clinically useful beta particles may be a source of radiation-induced dama

75 and Auger electrons, with its medium-energy beta(-)-particles, may enable the elimination of single

76 cy using radionuclides that emit short-range beta particles or conversion electrons (CEs).

77 by using radionuclides that emit short-range beta particles or conversion electrons.

78 Snrc radiation transport code for photon and beta-particle organ dosimetry.

79 The ability to image beta particles, positrons, and conversion electrons make

80 es, covering electrons, alpha-particles, and beta-particles purified and in equilibrium where appropr

81 al [CI], 0.020, 0.028 mBq/m(3)) in the gross-beta particle radiation downwind.

82 igen (PSMA)-617 enables targeted delivery of beta-particle radiation to prostate cancer.

83 A-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the

84 617, even in patients who are refractory to beta-particle radiation, illustrate the potential of tar

85 alysts have an identical Pt loading, similar Beta particle size and acidity, but different internal s

86 llumination of a 183 MBq (63)Ni radioisotope beta particle source.

87 ideal for diagnostic purposes and generates beta(-) particles suitable for effective cancer radiothe

88 t localizes in skeletal metastases and emits beta particles that may be therapeutically beneficial.

89 d with no therapy, alpha- ((149)Tb-cm09) and beta(-)-particle therapy ((161)Tb-cm09) resulted in a ma

90 o kill tumors that are resistant to targeted beta-particle therapy, suggesting that targeted alpha-pa

91 r who were unresponsive to the corresponding beta-particle therapy.

92 is study, we directly compared alpha- versus beta-particle treatment, as well as a combination thereo

93 Auger/internal conversion [IC] electrons and beta(-) particles) were computed via Monte Carlo simulat

94 icles if >/=3 attributes are measured or for beta particles with five attributes measured.

95 above unpackaged p-i-n photodiodes to detect beta-particles with maximum efficiency.

96 dition, the cross-fire effect of high-energy beta(-)-particles within the bone and the marrow may del